We think they would've been higher without the exchange rate. We're pretty happy with our sales performance. That's where we expected them to be.

We've transformed (Wyeth) into one of the most innovative research organizations. We've added significant innovation in the last few years, and are intending to do the same in the next two.

Our September sales performance was softer than expected. However, when you consider our exceptional sales performance in July and August, lean inventories, and the competitive environment, we expected there would be some weakening in September sales.

We'll continue to adjust our staffing levels to the sales performance we have.

Our performance continues to be driven by robust sales of our innovative oncology products which have helped nearly double our revenues in a three-year time period.

Our performance was extremely strong reporting record sales for the fourth-quarter and fiscal year.